ASCO® 2025 Highlights: Presenter Vignette – Bjørn Grønberg
Bjørn Grønberg
MD, PhD
Norwegian University of Science and Technology
LBA8005
Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
